Drug-induced disease

Many reports in the literature discuss aspects of drug-induced disease or injury which do not necessarily identify particular drugs or classes of drugs and their associated adverse drug reactions.

Such references might focus on the diagnosis, clinical pathology, pharmacology, pharmacogenomics or treatment of a drug-induced diseases or injury. Or analyse drug-induced diseases in relation to particular groups of the population (the young, the elderly, gender).

This area of the literature is accommodated in the Litt database under the category ‘Drug-induced disease (General)’ with further classification under the categories: skin; cardiovascular; central nervous system; endocrine/metabolic; gastrointestinal/hepatic etc. Litt’s weekly ‘Drug updates’ for subscribers lists ‘Drug-induced disease (General)’ as a separate heading with PubMed hyperlinks to references under these categories.

Drug-induced disease (Cardiovascular)

(2025): Kundnani NR+, Medicina (Kaunas) 61(4), 709 [REVIEW]
(2025): Ren G+, BMC Pharmacol Toxicol 26(1), 27 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ren G+, Sci Rep 15(1), 10359 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ren G+, Front Cardiovasc Med May (e-Collection) [REVIEW] (cardiac arrest) (pharmacovigilance / pharmacoepidemiology)
(2025): Sugiyama A+, J Pharmacol Exp Ther 392(2), 100023 [REVIEW]
(2024): Chaudhary KW+, Clin Transl Sci 17(12), e70098 [REVIEW]
(2024): Groth O+, MMW Fortschr Med (German) 166(19), 48-51
(2024): Huang Y+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Lee S+, Eur J Haematol Jun, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Li B+, Arrhythm Electrophysiol Rev 13, e06 [REVIEW]
(2024): Liu L+, Semin Cancer Biol Oct, Online ahead of print [REVIEW]
(2024): Lopez-Medina AI+, Pharmacogenet Genomics Oct, Online ahead of print (pharmacogenomics)
(2024): Simon ST+, PLoS One 19(6), e0303261 [REVIEW] (pharmacogenomics)
(2024): Tan H+, Front Cardiovasc Med May (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): Tetterton-Kellner J+, Adv Drug Deliv Rev Jun, Online ahead of print [REVIEW]
(2024): Woosley RL+, Heart Rhythm 21(6), 969-970 [REVIEW]
(2024): Yan L+, Expert Opin Drug Saf Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Zhong Y+, Expert Opin Drug Saf Oct, Online ahead of print [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Central Nervous System)

(2025): Gui J+, Pharmaceuticals (Basel) 18(4), 498 [REVIEW] (pharmacovigilance / pharmacoepidemiology) (pharmacogenomics)
(2025): Kobayashi S+, J Sleep Res Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Liu H+, Int J Surg Jan, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Nic Ionmhain Ú+, Emerg Med Australas 37(3), e70065 [REVIEW] (hyperthermia)
(2025): Washist R+, Pediatr Phys Ther 37(1), 57-63 [REVIEW]
(2025): Xu L+, Ther Adv Neurol Disord Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhong R+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Althubyani AA+, Drugs Context Jul (e-Collection) [REVIEW]
(2024): Bakewell B+, Front Pharmacol May (e-Collection) (27 cases) [REVIEW]
(2024): Barbosa-Azevedo M+, Toxicol Appl Pharmacol Sep, Online ahead of print [REVIEW]
(2024): Dumont S+, J Sleep Res Sep, Online ahead of print [REVIEW]
(2024): Garg K+, Brain Res Bull Feb (e-Collection) [REVIEW]
(2024): Hu K+, Expert Opin Drug Saf Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Ismail O+, Eur J Clin Pharmacol Jul, Online ahead of print [REVIEW]
(2024): Jia B+, Expert Opin Drug Saf May, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Karatayev O+, Int J Mol Sci 25(15), 8341 [REVIEW]
(2024): Kikegawa M+, Pharmaceuticals (Basel) 17(8), 1099 [REVIEW]
(2024): Preti K+, Clin J Oncol Nurs 28(4), 351-357 [REVIEW]
(2024): Pruett DG+, J Commun Disord Nov, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Rissardo JP+, Medicina (Kaunas) 60(8), 1347 [REVIEW]
(2024): Shah VV+, JCO Precis Oncol 8, e2300312
(2024): Shaia JK+, J Neuroophthalmol Aug, Online ahead of print8%
(2024): Shatunova S+, Eur J Pharmacol Jul, Online ahead of print [REVIEW]
(2024): Sunwoo Y+, Medicina (Kaunas) 60(7), 1028 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Velasco R+, Eur J Neurol Jul, Online ahead of print
(2024): Wang K+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Wang Y+, Expert Opin Drug Saf Dec, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Zhao C+, J Neurol Jun, Online ahead of print [REVIEW]
(2023): Fusaroli M+, Psychiatry Clin Neurosci 77(3), 160-167 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2022): Horseman M+, Cureus 14(7), e27278 [REVIEW]
(2020): Tan MG+, Am J Clin Dermatol 21(2), 163-172 [REVIEW]

Drug-induced disease (Endocrine/Metabolic)

(2025): Ben Salem C+, Eur J Intern Med May, Online ahead of print (comment on Mannheimer B+, Eur J Intern Med, May 2025 (loc cit))
(2025): Borsari SF+, Praxis (Bern 1994) (German) 114(4), 149-153 [REVIEW] (adrenal insufficiency)
(2025): Mannheimer B+, Eur J Intern Med May, Online ahead of print [REVIEW]
(2025): Patel M+, Curr Atheroscler Rep 27(1), 52 [REVIEW]
(2025): Song B+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yang H+, Front Pharmacol Apr (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Ji X+, Expert Opin Drug Saf Sep, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Yang X+, Clin Epidemiol 16, 617-630 (pharmacovigilance / pharmacoepidemiology)
(2012): Deepinder F+, Expert Opin Drug Saf 11(5), 779-95 [REVIEW]

Drug-induced disease (Gastrointestinal/Hepatic)

(2025): Daly AK, Liver Int 45(1), e16191 [REVIEW] (liver injury) (pharmacogenomics)
(2025): Hu Q+, Front Pharmacol May (e-Collection) (drug-induced liver injury)
(2025): Kozielewicz DM+, Clin Exp Hepatol 11(1), 25-33 [REVIEW]
(2025): Maris BR+, Int J Mol Sci 26(5), 2006 [REVIEW]
(2025): Nakakuni M+, Pediatr Int 67(1), e15847 (pharmacovigilance / pharmacoepidemiology)
(2025): Olubamiwa AO+, Expert Opin Drug Metab Toxicol Jun, Online ahead of print [REVIEW]
(2025): Wang P+, Clin Res Hepatol Gastroenterol Jun, Online ahead of print
(2025): Xie H+, Front Pharmacol Apr (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Ye W+, PLoS One Feb (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhang W+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Zhu BK+, Sci Rep 15(1), 4783 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Alcorta A+, Pharmacol Ther Jul, Online ahead of print [REVIEW]
(2024): Bessone F+, Clin Gastroenterol Hepatol Jul, Online ahead of print [REVIEW]
(2024): Björnsson ES, Pharmaceuticals (Basel) 17(4), 520 [REVIEW]
(2024): Chen M+, Front Artif Intell Jun (e-Collection)
(2024): Cho FN+, BMC Infect Dis 24(1), 759 (pharmacogenomics)
(2024): Chow R+, Support Care Cancer 32(11), 736 [REVIEW]
(2024): de Castria TB+, Expert Opin Drug Saf Dec, Online ahead of print [REVIEW]
(2024): Domingo-Carnice A+, Med Clin (Barc) Oct, Online ahead of print
(2024): Gao G+, J Hepatol Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Huang Y+, Molecules 29(11), 2663 [REVIEW]
(2024): Li G+, Cell Mol Gastroenterol Hepatol May, Online ahead of print [REVIEW]
(2024): Li W+, Front Pharmacol Sep (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): López-Pascual E+, Int J Mol Sci 25(10), 5203 [REVIEW]
(2024): Ma X+, Clin Ther May, Online ahead of print (Roussel Uclaf Causality Assessment Method)
(2024): Müller SL+, Am J Case Rep 25, e944508 (1 case / male)
(2024): Pan H+, Gut Microbes Dec, Online ahead of print [REVIEW]
(2024): Ravikumar B+, Arch Dis Child Educ Pract Ed May, Online ahead of print [REVIEW]
(2024): Renaux Torres MC+, Support Care Cancer 32(7), 455 [REVIEW]
(2024): Saowapa S+, Proc (Bayl Univ Med Cent) 37(5), 841-850 [REVIEW]
(2024): Suzuki A+, Liver Int Nov, Online ahead of print [REVIEW]
(2024): Wang X+, J Cardiovasc Pharmacol Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Yu S+, Hepatol Int Jun, Online ahead of print
(2024): Zhang G+, Expert Opin Drug Saf Dec, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2023): Andrade RJ+, J Hepatol 79(3), 853-866 [REVIEW]
(2023): Lee AA+, Pancreatology 23(6), 569-573 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2023): Zhu R+, J Med Microbiol Nov (e-Collection) [REVIEW]
(2022): Tan CK+, World J Gastroenterol 28(24), 2654-2666 [REVIEW]
(1997): Desmet VJ, J Hepatol 26 Suppl 1, 31-5 [REVIEW]

Drug-induced disease (Genitourinary)

(2025): Tian X+, Sci Rep 15(1), 15760 [REVIEW] (erectile dysfunction) (pharmacovigilance / pharmacoepidemiology)
(2024): Dai X+, Front Pharmacol Jan (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Li D+, Expert Opin Drug Saf Aug, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Zheng F+, Expert Opin Drug Saf 23(11), 1419-1426, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Zheng F+, Expert Opin Drug Saf Nov, Online ahead of print (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Hair)

(2025): Gaumond SI+, Cancers (Basel) 17(3), 411 [REVIEW]
(2025): Hill RC+, Skin Appendage Disord 11(1), 63-69 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Ben Kridis W+, Breast Dis 43(1), 251-255 (72 cases)
(2022): Issa NT+, Dermatol Surg 48(8), 855-861 [REVIEW]

Drug-induced disease (Hematologic)

(2025): Wen X+, Int J Clin Pharm Jan, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Xia K+, Cancer Control May (e-Collection) [REVIEW] (myelosuppression) (pharmacovigilance / pharmacoepidemiology)
(2024): Lu Y+, Front Pharmacol Dec (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2023): Mazzierli T+, Front Pharmacol Jan (e-Collection) [REVIEW]
(2019): Vo QT+, Ann Pharmacother 53(5), 523-536 [REVIEW] (Naranjo Adverse Drug Reaction Probability Scale)

Drug-induced disease (Mucosal)

(2025): Nodit L+, Sci Data 12(1), 463
(2025): Xie C+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Amiri S+, Curr Drug Saf May, Online ahead of print [REVIEW]
(2024): Goel G+, J Cancer Res Ther 20(5), 1564-1569
(2024): Kouri M+, Curr Pain Headache Rep Jul, Online ahead of print [REVIEW]
(2024): Mohan MP+, Support Care Cancer 33(1), 22 (association)
(2024): Xu D+, Heliyon 10(19), e38561 (pharmacovigilance / pharmacoepidemiology)
(2018): Česák T+, Pituitary 21(6), 561-570 [REVIEW] (cerebrospinal fluid rhinorrhea)
(2017): Fortuna G+, Eur J Clin Pharmacol 73(12), 1523-1537 [REVIEW]
(2013): Özkaya E, J Am Acad Dermatol 69(2), e51-8 (61 cases)

Drug-induced disease (Nails)

(2024): Trivedi M+, Indian J Dermatol 69(3), 205-211
(2024): Yamamoto K+, Support Care Cancer 32(10), 647

Drug-induced disease (Neuromuscular/Skeletal)

(2025): Boyne N+, BMC Med Res Methodol 25(1), 33 [REVIEW]
(2025): Nikitina V+, J Clin Med 14(5), 1644 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Rissardo JP+, Medicina (Kaunas) 61(1), 131 [REVIEW]
(2025): Sridharan K, Curr Pediatr Rev May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Ocular)

(2025): Aftab OM+, J Ocul Pharmacol Ther May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Khanani I+, Int Ophthalmol Clin 65(1), 3-7 (e-Collection) [REVIEW]
(2024): Ang T+, Surv Ophthalmol 69(4), 622-631 [REVIEW]
(2024): Cannilla H+, Tremor Other Hyperkinet Mov (N Y) May (e-Collection) [REVIEW]
(2024): Chen XD+, Front Pharmacol Dec (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): Lavasidis G+, Crit Rev Oncol Hematol Jun, Online ahead of print [REVIEW]
(2024): Li L+, Front Endocrinol (Lausanne) May (e-Collection) [REVIEW] (Graves’ ophthalmopathy)
(2024): Pepose JS+, Ophthalmology Sep, Online ahead of print
(2024): Wu SN+, Transl Vis Sci Technol 13(9), 17 (pharmacovigilance / pharmacoepidemiology)
(2023): Hu Y+, Front Endocrinol (Lausanne) May (e-Collection) [REVIEW] (Graves’ ophthalmopathy)
(2007): Lloyd MJ+, Drugs Today (Barc) 43(11), 827-36 [REVIEW]
(2004): Hollander DA+, Curr Opin Ophthalmol 15(6), 541-8 [REVIEW]

Drug-induced disease (Other)

(2025): Chen S+, Discov Oncol 16(1), 786 [REVIEW] (drug-induced second tumors) (pharmacovigilance / pharmacoepidemiology)
Negative findings
(2024): Pivato CA+, Eur Heart J Dec, Online ahead of print [REVIEW] ("these findings suggest the cardiovascular safety of fertility treatments")
Negative findings
(2024): Zeng Y+, Andrology Oct, Online ahead of print (pharmacovigilance / pharmacoepidemiology)

Drug-induced disease (Otic)

(2025): Wu T+, Hear Res Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Li B+, Front Pharmacol Nov (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2021): Maia NPD+, Int Braz J Urol 47(4), 747-752 [REVIEW]

Drug-induced disease (Renal)

(2025): Ding P+, Front Pharmacol Mar (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Oliveira CL+, Int J Clin Pharm May, Online ahead of print (pharmacovigilance / pharmacoepidemiology)
(2024): Connor S+, Toxicol Res (Camb) Aug (e-Collection) [REVIEW]
(2024): Cousin F+, Rev Med Liege (French) 79(5-6), 418-423
(2024): Ganguli A+, J Assoc Physicians India 72(1), 74-80 [REVIEW]
(2024): Garcia G+, Front Med (Lausanne) Oct (e-Collection)
(2024): Joung JY+, Pharmaceuticals (Basel) 17(5), 544 [REVIEW]
(2024): Lyrio RMDC+, Front Nephrol Aug, Online ahead of print [REVIEW]
(2024): Yu CH+, Medicina (Kaunas) 60(8), 1302 [REVIEW]

Drug-induced disease (Respiratory)

(2025): Kamath A, Sci Rep 15(1), 1455 (pharmacovigilance / pharmacoepidemiology)
(2025): Wang E+, Expert Opin Drug Saf Mar, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): Yamanaka M+, Respir Investig 63(4), 524-531 [REVIEW]
(2024): Annareddy S+, Cureus 16(9), e69954 [REVIEW]
(2024): Butranova OI+, Biomedicines 12(12), 2650 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Cörüt R+, Cureus 16(6), e63408 (20 cases)
(2024): Shen Y+, Int Immunopharmacol Jun, Online ahead of print [REVIEW]
(2024): Shroff GS+, Clin Chest Med 45(2), 325-337 [REVIEW]
(2020): Hayashi R+, Anesth Prog 67(4), 214-218 (1 case / male)

Drug-induced disease (Skin)

(2025): Etesami I+, J Skin Cancer Feb (e-Collection) [REVIEW]
(2025): Ge L+, Sci Rep 15(1), 18102 [REVIEW] (photosensitivity) (pharmacovigilance / pharmacoepidemiology)
(2025): Jiamsathit W+, J Clin Med 14(3), 857
(2025): Jin Q+, Expert Opin Drug Saf Feb, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2025): R Bray E+, J Drugs Dermatol 24(5), 476-481 [REVIEW]
(2025): Xia J+, Front Pharmacol Mar (e-Collection) [REVIEW] (pharmacovigilance / pharmacoepidemiology)
(2024): Brameli A+, J Allergy Clin Immunol Pract Jun, Online ahead of print [REVIEW]
(2024): Bray ER+, Arch Dermatol Res 316(6), 233 (ICI-associated epidermal necrosis should be considered a distinct clinical entity from drug-induced SJS/TEN.)
(2024): Chow TG+, Curr Opin Pediatr Aug, Online ahead of print [REVIEW]
(2024): Cole DW+, Am J Dermatopathol 46(6), 337-345
(2024): Fan M+, Front Pharmacol Jul (e-Collection) (pharmacovigilance / pharmacoepidemiology)
(2024): Hung SI+, Nat Rev Dis Primers 10(1), 30 [REVIEW]
(2024): Jiménez-Andrade Y+, Hematol Oncol Clin North Am Jun, Online ahead of print [REVIEW]
(2024): Kemanetzi C+, Dermatol Pract Concept Jul (e-Collection)
(2024): Lu Y+, Front Immunol Jul (e-Collection) (63 cases)
(2024): Rijal H+, J Cutan Med Surg 28(5), 496-497 [REVIEW]
(2024): Samarakoon U+, J Am Acad Dermatol Apr, Online ahead of print
(2024): Temido MJ+, Am J Gastroenterol Oct, Online ahead of print [REVIEW]
(2024): Tetart F+, J Eur Acad Dermatol Venereol Jul [REVIEW]
(2024): Ubukata N+, J Am Acad Dermatol May, Online ahead of print [REVIEW]
(2023): Etesami I+, Australas J Dermatol 64(1), 41-49 [REVIEW]
(2023): Parisi R+, Am J Clin Dermatol 24(4), 557-575 [REVIEW]
(2022): Del Pozzo-Magaña BR+, Br J Clin Pharmacol Aug, Online ahead of print [REVIEW]
(2021): Montastruc JL+, Eur J Clin Pharmacol 77(10), 1587-1588 (pharmacovigilance / pharmacoepidemiology)
(2021): Schuler AM+, J Cutan Pathol 48(12), 1471-1479 [REVIEW]
(2021): Shah N+, Am J Clin Dermatol 22(1), 39-53 [REVIEW]
(2020): Anthony N+, Fundam Clin Pharmacol 34(6), 736-742 [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Litt's app available free to subscribers

Search drug eruptions and reactions data anytime, anywhere